
Agilent Technologies, Inc.
NYSE•A
CEO: Mr. Rodney Gonsalves
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact Information
Market Cap
$39.02B
P/E (TTM)
29.9
36.6
Dividend Yield
0.7%
52W High
$160.27
52W Low
$96.43
52W Range
Rank25Top 8.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q4 2025 Data
Revenue
$1.86B+9.41%
4-Quarter Trend
EPS
$1.53+24.39%
4-Quarter Trend
FCF
$452.00M+16.50%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Increased 6% Nine months revenue reached $5.09B, up 6% compared to prior year; growth across all segments noted.
Life Sciences Segment Leads Growth Life Sciences segment revenue grew 14% for the quarter and 9% for nine months, driven by BIOVECTRA.
Operating Cash Flow Strong Net cash provided by operating activities totaled $1.01B for nine months, despite a decrease from 2024.
Stock Repurchases Continue Repurchased 2.734M shares for $340M during nine months ended July 31, 2025 under 2023 plan.
Risk Factors
Net Income Declined 7% Nine months net income fell to $869M from $938M last year; diluted EPS decreased to $3.05.
Gross Margin Compression Noted Total gross margin decreased 2 percentage points to 52.2% for nine months due to tariffs and mix.
Tariff Impact on Costs Recent tariff changes adversely impacted cost of revenue in Q3; mitigation expected in fiscal year 2026.
Limited Market Visibility Quarterly results highly dependent on order timing, which is difficult to forecast; customer capital budgets constrained.
Outlook
FY2025 Restructuring Completion FY25 Plan expected to substantially complete restructuring activities by second quarter fiscal year 2026.
Capital Spending Planned Expect total capital expenditures for the current year to be approximately $400M, focused on manufacturing expansion.
Focus on Differentiated Solutions Primary focus remains enhancing customer experience and delivering differentiated product solutions for long-term growth.
FY2025 Plan Cost Savings FY25 Plan expected to yield $75M to $80M in annual cost of sales and operating expense reduction.
Peer Comparison
Revenue (TTM)
CAH$234.31B
TAK$29.67B
$21.43B
Gross Margin (Latest Quarter)
77.9%
TAK65.8%
64.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IDXX | $54.48B | 53.2 | 67.8% | 32.9% |
| EW | $50.61B | 36.9 | 13.4% | 5.3% |
| TAK | $49.28B | 55.3 | 1.9% | 32.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.4%
Moderate Growth
4Q Net Income CAGR
10.9%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 25, 2026
EPS:$1.37
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Jul 31, 2025|Filed: Aug 29, 2025|Revenue: $1.74B+10.1%|EPS: $1.18+21.6%MissForm 10-Q - Q2 2025
Period End: Apr 30, 2025|Filed: Jun 2, 2025|Revenue: $1.67B+6.0%|EPS: $0.75-28.6%MissForm 10-Q - Q1 2025
Period End: Jan 31, 2025|Filed: Mar 3, 2025|Revenue: $1.68B+1.4%|EPS: $1.12-5.9%MissForm 10-K - FY 2024
Period End: Oct 31, 2024|Filed: Dec 20, 2024|Revenue: $6.51B-4.7%|EPS: $4.44+5.2%BeatForm 10-Q - Q3 2024
Period End: Jul 31, 2024|Filed: Aug 30, 2024|Revenue: $1.58B-5.6%|EPS: $0.97+155.3%MissForm 10-Q - Q2 2024
Period End: Apr 30, 2024|Filed: Jun 3, 2024|Revenue: $1.57B-8.4%|EPS: $1.05+2.9%MissForm 10-Q - Q1 2024
Period End: Jan 31, 2024|Filed: Mar 5, 2024|Revenue: $1.66B-5.6%|EPS: $1.19+0.0%MeetForm 10-K - FY 2023
Period End: Oct 31, 2023|Filed: Dec 20, 2023|Revenue: $6.83B-0.2%|EPS: $4.22+0.7%Beat